MEDI 9197

Drug Profile

MEDI 9197

Alternative Names: Injectable 3M 052; MEDI9197

Latest Information Update: 24 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 3M Drug Delivery Systems
  • Developer MedImmune
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 05 Apr 2017 Pharmacodynamics and safety data from a phase I trial in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 30 Sep 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (Intratumoural) (NCT02556463)
  • 25 Sep 2015 Medimmune in-licenses injectable MEDI 9197 from 3M Drug Delivery Systems
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top